These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 11821581)

  • 1. Chinese herbal formula XQ-9302: pilot study of its clinical and in vitro activity against human immunodeficiency virus.
    Kang LY; Pan XZ; Yang WX; Pan QC; Weng XH; Yang WQ
    Hong Kong Med J; 1999 Jun; 5(2):135-139. PubMed ID: 11821581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma.
    Furrer H; Barloggio A; Egger M; Garweg JG;
    Ophthalmology; 2003 Feb; 110(2):432-6. PubMed ID: 12578793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ CCR5+ T-cell dynamics during simian immunodeficiency virus infection of Chinese rhesus macaques.
    Monceaux V; Viollet L; Petit F; Cumont MC; Kaufmann GR; Aubertin AM; Hurtrel B; Silvestri G; Estaquier J
    J Virol; 2007 Dec; 81(24):13865-75. PubMed ID: 17898067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years.
    Zhou HY; Zheng YH; Zhang CY; Chen J; He Y; Ding PP; Li H
    Viral Immunol; 2007; 20(1):180-7. PubMed ID: 17425432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary efficacy and safety of oral suspension SH, combination of five chinese medicinal herbs, in people living with HIV/AIDS ; the phase I/II study.
    Kusum M; Klinbuayaem V; Bunjob M; Sangkitporn S
    J Med Assoc Thai; 2004 Sep; 87(9):1065-70. PubMed ID: 15516007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of medicinal herbs by human immunodeficiency virus-infected patients.
    Kassler WJ; Blanc P; Greenblatt R
    Arch Intern Med; 1991 Nov; 151(11):2281-8. PubMed ID: 1953234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue.
    Murakami T; Eda Y; Nakasone T; Ami Y; Someya K; Yoshino N; Kaizu M; Izumi Y; Matsui H; Shinohara K; Yamamoto N; Honda M
    AIDS; 2009 Jul; 23(12):1485-94. PubMed ID: 19528788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.
    Cao Y; Qin L; Zhang L; Safrit J; Ho DD
    N Engl J Med; 1995 Jan; 332(4):201-8. PubMed ID: 7808485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of low-dose zidovudine in human immunodeficiency virus infection.
    Collier AC; Bozzette S; Coombs RW; Causey DM; Schoenfeld DA; Spector SA; Pettinelli CB; Davies G; Richman DD; Leedom JM
    N Engl J Med; 1990 Oct; 323(15):1015-21. PubMed ID: 1977080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in soluble factor-mediated CD8+ cell-derived antiviral activity in cynomolgus macaques infected with simian immunodeficiency virus SIVmac251: relationship to biological markers of progression.
    Dioszeghy V; Benlhassan-Chahour K; Delache B; Dereuddre-Bosquet N; Aubenque C; Gras G; Le Grand R; Vaslin B
    J Virol; 2006 Jan; 80(1):236-45. PubMed ID: 16352548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A clinical trial using zidovudine and lamivudine plus indinavir triple therapy in Chinese individuals with human immunodeficiency virus infection].
    Cao Y; Zhang F; Mei S; Li L; Gao M; Ding Y; Cai W
    Zhonghua Nei Ke Za Zhi; 2002 Feb; 41(2):109-13. PubMed ID: 11940307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
    Carcelain G; Tubiana R; Samri A; Calvez V; Delaugerre C; Agut H; Katlama C; Autran B
    J Virol; 2001 Jan; 75(1):234-41. PubMed ID: 11119593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
    Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
    N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective and anti-human immunodeficiency virus activity of minocycline.
    Zink MC; Uhrlaub J; DeWitt J; Voelker T; Bullock B; Mankowski J; Tarwater P; Clements J; Barber S
    JAMA; 2005 Apr; 293(16):2003-11. PubMed ID: 15855434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro cytopathogenicity of the human immunodeficiency virus (HIV)-1 predicts survival in HIV-infected hemophiliacs independent from CD4 cell count.
    Rockstroh JK; Woitas RP; Brackmann HH; Kupfer B; Kaiser R; Schneweis KE; Sudhop T; Spengler U
    Eur J Med Res; 1998 May; 3(5):223-30. PubMed ID: 9580568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement.
    Ledergerber B; Flepp M; Böni J; Tomasik Z; Cone RW; Lüthy R; Schüpbach J
    J Infect Dis; 2000 Apr; 181(4):1280-8. PubMed ID: 10751136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.